SUGAR LAND, Texas, Sept. 18, 2017 /PRNewswire/ -- Researched by Annette Kreuger, Industrial Info Resources --Biological drug maker Genentech, the developer of the blockbuster cancer drug Avastin, was dealt a stunning blow on September 14 when the U.S. Food and Drug Administration approved a biosimilar (generic biological drug). The biosimilar, Mvasi (bevacizumab-awwb), the result of a partnership between Amgen and Allergan, was approved for certain colorectal, lung, brain, kidney and cervical cancers.
For details, view the entire article by subscribing to Industrial Info's Premium Industry News, or browse other breaking industrial news stories at www.industrialinfo.com.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle™, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. To contact an office in your area, visit the www.industrialinfo.com "Contact Us" page.
SOURCE Industrial Info Resources, Inc.